Andreas Drolz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andreas Drolz has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Roedl
Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
7 shared publications - Michael Trauner
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
7 shared publications - Karoline Rutter
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
6 shared publications - Thomas Horvatits
I. Department of Medicine, Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6 shared publications - Valentin Fuhrmann
Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
5 shared publications Valentin Fuhrmann
Department of Intensive Care Medicine University Medical Center Hamburg‐Eppendorf Hamburg Germany
4 shared publications
Latest Publications
- 13 August 2024
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 119 (6) , 1-7
Blutungen bei Lebererkrankungen
- 13 August 2024
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 119 (6) , 1-7
Blutungen bei Lebererkrankungen
- Open Access
- 27 January 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (3) , 339-351
High vaccination coverage and infection rate result in a robust SARS‐CoV‐2‐specific immunity in the majority of liver cirrhosis and transplant patients: A single‐center cross‐sectional study
Background: In the third year of the SARS‐CoV‐2 pandemic, little is known about the vaccine‐ and infection‐induced immune response in liver transplant recipients (LTR) and liver cirrhosis patients (LCP).Objective: This cross‐sectional study assessed the vaccination coverage, infection rate, and the resulting humoral and cellular SARS‐CoV‐2‐specific immune responses in a cohort of LTR and LCP at the University Medical Center Hamburg‐Eppendorf, Germany between March and May 2023.Methods: Clinical and laboratory data from 244 consecutive patients (160 LTR and 84 LCP) were collected via chart review and a patient survey. Immune responses were determined via standard spike(S)‐ and nucleocapsid‐protein serology and a spike‐specific Interferon‐gamma release assay (IGRA).Results: On average, LTR and LCP were vaccinated 3.7 and 3.3 times, respectively and 59.4% of patients received ≥4 vaccinations. Altogether, 68.1% (109/160) of LTR and 70.2% (59/84) of LCP experienced a SARS‐CoV‐2 infection. Most infections occurred during the Omicron wave in 2022 after an average of 3.0 vaccinations. Overall, the hospitalization rate was low (<6%) in both groups. An average of 4.3 antigen contacts by vaccination and/or infection resulted in a seroconversion rate of 98.4%. However, 17.5% (28/160) of LTR and 8.3% (7/84) of LCP demonstrated only low anti‐S titers (<1000 AU/ml), and 24.6% (16/65) of LTR and 20.4% (10/59) of LCP had negative or low IGRA responses. Patients with hybrid immunity (vaccination plus infection) elicited significantly higher anti‐S titers compared with uninfected patients with the same number of spike antigen contacts. A total of 22.2% of patients refused additional booster vaccinations.Conclusion: By spring 2023, high vaccination coverage and infection rate have resulted in a robust, mostly hybrid, humoral and cellular immune response in most LTR and LCP. However, booster vaccinations with vaccines covering new variants seem advisable, especially in patients with low immune responses and risk factors for severe disease.
- 27 January 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (3) , 339-351
Open AccessHigh vaccination coverage and infection rate result in a robust SARS‐CoV‐2‐specific immunity in the majority of liver cirrhosis and transplant patients: A single‐center cross‐sectional study
Background: In the third year of the SARS‐CoV‐2 pandemic, little is known about the vaccine‐ and infection‐induced immune response in liver transplant recipients (LTR) and liver cirrhosis patients (LCP).Objective: This cross‐sectional study assessed the vaccination coverage, infection rate, and the resulting humoral and cellular SARS‐CoV‐2‐specific immune responses in a cohort of LTR and LCP at the University Medical Center Hamburg‐Eppendorf, Germany between March and May 2023.Methods: Clinical and laboratory data from 244 consecutive patients (160 LTR and 84 LCP) were collected via chart review and a patient survey. Immune responses were determined via standard spike(S)‐ and nucleocapsid‐protein serology and a spike‐specific Interferon‐gamma release assay (IGRA).Results: On average, LTR and LCP were vaccinated 3.7 and 3.3 times, respectively and 59.4% of patients received ≥4 vaccinations. Altogether, 68.1% (109/160) of LTR and 70.2% (59/84) of LCP experienced a SARS‐CoV‐2 infection. Most infections occurred during the Omicron wave in 2022 after an average of 3.0 vaccinations. Overall, the hospitalization rate was low (<6%) in both groups. An average of 4.3 antigen contacts by vaccination and/or infection resulted in a seroconversion rate of 98.4%. However, 17.5% (28/160) of LTR and 8.3% (7/84) of LCP demonstrated only low anti‐S titers (<1000 AU/ml), and 24.6% (16/65) of LTR and 20.4% (10/59) of LCP had negative or low IGRA responses. Patients with hybrid immunity (vaccination plus infection) elicited significantly higher anti‐S titers compared with uninfected patients with the same number of spike antigen contacts. A total of 22.2% of patients refused additional booster vaccinations.Conclusion: By spring 2023, high vaccination coverage and infection rate have resulted in a robust, mostly hybrid, humoral and cellular immune response in most LTR and LCP. However, booster vaccinations with vaccines covering new variants seem advisable, especially in patients with low immune responses and risk factors for severe disease.
- Open Access
- 25 August 2022
- Published by Wiley in Liver International
- Vol. 43 (1) , 180-193
Pulmonary impairment independently determines mortality in critically ill patients with acute‐on‐chronic liver failure
Background & Aims: In ACLF patients, an adequate risk stratification is essential, especially for liver transplant allocation, since ACLF is associated with high short‐term mortality. The CLIF‐C ACLF score is the best prognostic model to predict outcome in ACLF patients. While lung failure is generally regarded as signum malum in ICU care, this study aims to evaluate and quantify the role of pulmonary impairment on outcome in ACLF patients. Methods: In this retrospective study, 498 patients with liver cirrhosis and admission to IMC/ICU were included. ACLF was defined according to EASL‐CLIF criteria. Pulmonary impairment was classified into three groups: unimpaired ventilation, need for mechanical ventilation and defined pulmonary failure. These factors were analysed in different cohorts, including a propensity score‐matched ACLF cohort. Results: Mechanical ventilation and pulmonary failure were identified as independent risk factors for increased short‐term mortality. In matched ACLF patients, the presence of pulmonary failure showed the highest 28‐day mortality (83.7%), whereas mortality rates in ACLF with mechanical ventilation (67.3%) and ACLF without pulmonary impairment (38.8%) were considerably lower ( p < .001). Especially in patients with pulmonary impairment, the CLIF‐C ACLF score showed poor predictive accuracy. Adjusting the CLIF‐C ACLF score for the grade of pulmonary impairment improved the prediction significantly. Conclusions: This study highlights that not only pulmonary failure but also mechanical ventilation is associated with worse prognosis in ACLF patients. The grade of pulmonary impairment should be considered in the risk assessment in ACLF patients. The new score may be useful in the selection of patients for liver transplantation.
- 25 August 2022
- Published by Wiley in Liver International
- Vol. 43 (1) , 180-193
Open AccessPulmonary impairment independently determines mortality in critically ill patients with acute‐on‐chronic liver failure
Background & Aims: In ACLF patients, an adequate risk stratification is essential, especially for liver transplant allocation, since ACLF is associated with high short‐term mortality. The CLIF‐C ACLF score is the best prognostic model to predict outcome in ACLF patients. While lung failure is generally regarded as signum malum in ICU care, this study aims to evaluate and quantify the role of pulmonary impairment on outcome in ACLF patients. Methods: In this retrospective study, 498 patients with liver cirrhosis and admission to IMC/ICU were included. ACLF was defined according to EASL‐CLIF criteria. Pulmonary impairment was classified into three groups: unimpaired ventilation, need for mechanical ventilation and defined pulmonary failure. These factors were analysed in different cohorts, including a propensity score‐matched ACLF cohort. Results: Mechanical ventilation and pulmonary failure were identified as independent risk factors for increased short‐term mortality. In matched ACLF patients, the presence of pulmonary failure showed the highest 28‐day mortality (83.7%), whereas mortality rates in ACLF with mechanical ventilation (67.3%) and ACLF without pulmonary impairment (38.8%) were considerably lower ( p < .001). Especially in patients with pulmonary impairment, the CLIF‐C ACLF score showed poor predictive accuracy. Adjusting the CLIF‐C ACLF score for the grade of pulmonary impairment improved the prediction significantly. Conclusions: This study highlights that not only pulmonary failure but also mechanical ventilation is associated with worse prognosis in ACLF patients. The grade of pulmonary impairment should be considered in the risk assessment in ACLF patients. The new score may be useful in the selection of patients for liver transplantation.
- 24 August 2021
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 116 (6) , 482-490
Klinisches Bild der Blutung bei kritisch kranken Patienten auf der Intensivstation
- 24 August 2021
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 116 (6) , 482-490
Klinisches Bild der Blutung bei kritisch kranken Patienten auf der Intensivstation
- Open Access
- 24 June 2021
- Published by Springer Nature in International Journal of Obesity
- Vol. 45 (10) , 2197-2204
Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
Background: Non-invasive scores, such as the non-alcoholic fatty liver disease (NAFLD) Fibrosis Score (NFS), are increasingly used for liver fibrosis assessment in patients with NAFLD. The aim of this study was to assess the applicability and reliability of non-invasive fibrosis scores in NAFLD patients with and without morbid obesity. Methods: Three hundred sixty-eight patients with biopsy-proven NAFLD identified between January 2012 and December 2015 were studied; 225 with morbid obesity (biopsy obtained during bariatric surgery) and 143 patients without (termed as “conventional”). Results: Median age was 47 years, 57% were female. Median body mass index (BMI) was 42.9 kg/m2 with significant differences between our conventional and morbidly obese patients (BMI 29.0 vs. 50.8 kg/m2, p < 0.001). Overall, 42% displayed mild/moderate and 16% advanced liver fibrosis (stage III/IV). All tested scores were significantly linked to fibrosis stage (p < 0.001 for all). FIB-4 (AUROC 0.904), APRI (AUROC 0.848), and NFS (AUROC 0.750) were identified as potent predictors of advanced fibrosis, although NFS overestimated fibrosis stage in morbid obesity. Limiting BMI to a maximum of 40 kg/m2 improved NFS’ overall performance (AUROC 0.838). FIB-4 > 1.0 indicated high probability of advanced fibrosis (OR = 29.1). FIB-4 predicted advanced fibrosis independently from age, sex, BMI, and presence of morbid obesity. Conclusions: Our data suggest that FIB-4 score is an accurate predictor of advanced fibrosis in NAFLD throughout all BMI stages. Without adjustment, NFS tends to overestimate fibrosis in morbidly obese NAFLD patients. This problem may be solved by implementation of an upper BMI limit (for NFS) or adjustment of diagnostic thresholds.
- 24 June 2021
- Published by Springer Nature in International Journal of Obesity
- Vol. 45 (10) , 2197-2204
Open AccessPerformance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
Background: Non-invasive scores, such as the non-alcoholic fatty liver disease (NAFLD) Fibrosis Score (NFS), are increasingly used for liver fibrosis assessment in patients with NAFLD. The aim of this study was to assess the applicability and reliability of non-invasive fibrosis scores in NAFLD patients with and without morbid obesity. Methods: Three hundred sixty-eight patients with biopsy-proven NAFLD identified between January 2012 and December 2015 were studied; 225 with morbid obesity (biopsy obtained during bariatric surgery) and 143 patients without (termed as “conventional”). Results: Median age was 47 years, 57% were female. Median body mass index (BMI) was 42.9 kg/m2 with significant differences between our conventional and morbidly obese patients (BMI 29.0 vs. 50.8 kg/m2, p < 0.001). Overall, 42% displayed mild/moderate and 16% advanced liver fibrosis (stage III/IV). All tested scores were significantly linked to fibrosis stage (p < 0.001 for all). FIB-4 (AUROC 0.904), APRI (AUROC 0.848), and NFS (AUROC 0.750) were identified as potent predictors of advanced fibrosis, although NFS overestimated fibrosis stage in morbid obesity. Limiting BMI to a maximum of 40 kg/m2 improved NFS’ overall performance (AUROC 0.838). FIB-4 > 1.0 indicated high probability of advanced fibrosis (OR = 29.1). FIB-4 predicted advanced fibrosis independently from age, sex, BMI, and presence of morbid obesity. Conclusions: Our data suggest that FIB-4 score is an accurate predictor of advanced fibrosis in NAFLD throughout all BMI stages. Without adjustment, NFS tends to overestimate fibrosis in morbidly obese NAFLD patients. This problem may be solved by implementation of an upper BMI limit (for NFS) or adjustment of diagnostic thresholds.
- Open Access
- 9 December 2019
- Published by Springer Nature in Critical Care
- Vol. 23 (1) , 1-8
Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)
Background: Critically ill patients in the intensive care unit (ICU) are at high risk for developing Clostridioides difficile infections (CDI). Risk factors predicting their mortality or standardized treatment recommendations have not been defined for this cohort. Our goal is to determine outcome and mortality associated risk factors for patients at the ICU with CDI by evaluating clinical characteristics and therapy regimens. Methods: A retrospective single-centre cohort study. One hundred forty-four patients (0.4%) with CDI-associated diarrhoea were included (total 36.477 patients admitted to 12 ICUs from January 2010 to September 2015). Eight patients without specific antibiotic therapy were excluded, so 132 patients were analysed regarding mortality, associated risk factors and therapy regimens using univariate and multivariate regression. Results: Twenty-eight-day mortality was high in patients diagnosed with CDI (27.3%) compared to non-infected ICU patients (9%). Patients with non CDI-related sepsis (n = 40/132; 30.3%) showed further increase in 28-day mortality (45%; p = 0.003). Initially, most patients were treated with a single CDI-specific agent (n = 120/132; 90.9%), either metronidazole (orally, 35.6%; or IV, 37.1%) or vancomycin (18.2%), or with a combination of antibiotics (n = 12/132; 9.1%). Patients treated with metronidazole IV showed significantly longer duration of diarrhoea > 5 days (p = 0.006). In a multivariate regression model, metronidazole IV as initial therapy was an independent risk factor for delayed clinical cure. Immunosuppressants (p = 0.007) during ICU stay lead to increased 28-day mortality. Conclusion: Treatment of CDI with solely metronidazole IV leads to a prolonged disease course in critically ill patients.
- 9 December 2019
- Published by Springer Nature in Critical Care
- Vol. 23 (1) , 1-8
Open AccessInitial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)
Background: Critically ill patients in the intensive care unit (ICU) are at high risk for developing Clostridioides difficile infections (CDI). Risk factors predicting their mortality or standardized treatment recommendations have not been defined for this cohort. Our goal is to determine outcome and mortality associated risk factors for patients at the ICU with CDI by evaluating clinical characteristics and therapy regimens. Methods: A retrospective single-centre cohort study. One hundred forty-four patients (0.4%) with CDI-associated diarrhoea were included (total 36.477 patients admitted to 12 ICUs from January 2010 to September 2015). Eight patients without specific antibiotic therapy were excluded, so 132 patients were analysed regarding mortality, associated risk factors and therapy regimens using univariate and multivariate regression. Results: Twenty-eight-day mortality was high in patients diagnosed with CDI (27.3%) compared to non-infected ICU patients (9%). Patients with non CDI-related sepsis (n = 40/132; 30.3%) showed further increase in 28-day mortality (45%; p = 0.003). Initially, most patients were treated with a single CDI-specific agent (n = 120/132; 90.9%), either metronidazole (orally, 35.6%; or IV, 37.1%) or vancomycin (18.2%), or with a combination of antibiotics (n = 12/132; 9.1%). Patients treated with metronidazole IV showed significantly longer duration of diarrhoea > 5 days (p = 0.006). In a multivariate regression model, metronidazole IV as initial therapy was an independent risk factor for delayed clinical cure. Immunosuppressants (p = 0.007) during ICU stay lead to increased 28-day mortality. Conclusion: Treatment of CDI with solely metronidazole IV leads to a prolonged disease course in critically ill patients.
- 1 April 2019
- Published by Elsevier in Resuscitation
- Vol. 137, 175-182
Hypoxic liver injury after in- and out-of-hospital cardiac arrest: Risk factors and neurological outcome
- 1 April 2019
- Published by Elsevier in Resuscitation
- Vol. 137, 175-182
Hypoxic liver injury after in- and out-of-hospital cardiac arrest: Risk factors and neurological outcome
- Open Access
- 19 April 2018
- Published by Elsevier in Annals of Intensive Care
- Vol. 8 (1) , 48-12
Acid–base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease
- 19 April 2018
- Published by Elsevier in Annals of Intensive Care
- Vol. 8 (1) , 48-12
Open AccessAcid–base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S558-S559
Performance and reliability of non-invasive fibrosis scores in nonalcoholic fatty liver disease with and without morbid obesity
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S558-S559
Performance and reliability of non-invasive fibrosis scores in nonalcoholic fatty liver disease with and without morbid obesity
- 1 December 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 56 (01) , 43-50
Kombination von NAFLD Fibrosis Score und transienter Elastografie zur Identifikation mittelgradiger Fibrosestadien (II/III) bei nicht-alkoholischer Fettlebererkrankung
Einleitung Die nicht-alkoholische Fettlebererkrankung (NAFLD) gehört mittlerweile weltweit zu den häufigsten Ursachen für eine chronische Leberschädigung. Aktuell sind die therapeutischen Optionen limitiert und neue pharmakologische Therapieoptionen werden primär im Rahmen von Studien untersucht. Da viele aktuelle Studien zumeist auf NAFLD-Patienten mit den Fibrosestadien II und III (nach Kleiner) abzielen, ist die nicht-invasive Identifikation dieser Patienten von zunehmender Bedeutung. Ziel Evaluation von Lebersteifigkeitsmessung (LSM) und NAFLD Fibrosis Score (NFS) im Hinblick auf die Vorhersage eines Fibrosestadiums II/III. Methoden Patienten mit bioptisch gesicherter NAFLD Diagnose wurden in die Studie eingeschlossen. Vor der Leberbiopsie wurden alle Patienten klinisch, laborchemisch und mittels LSM evaluiert. Anschließend wurde die Vorhersagekraft von NFS und LSM im Hinblick auf das Vorliegen einer Fibrose Stadium II/III untersucht. Ergebnisse 134 NALFD-Patienten wurden in die Studie eingeschlossen und untersucht. Das mittlere Alter betrug 53 (IQR 36 – 60) Jahre, 55 Patienten (41 %) waren weiblich. 82 % der Patienten waren übergewichtig/adipös mit typischen Befundkonstellationen des Metabolischen Syndroms. 84 Patienten (66 %) zeigten Zeichen einer Fibrose, bei 42 (50 %) bestand eine fortgeschrittene Fibrose. LSM und NFS korrelierten mit dem Fibrosestadium (r = 0,696 bzw. r = 0,685, p < 0,01). NFS-Werte zwischen –2,0 und + 0,5 und LSM-Werte zwischen 8 und 22kPa waren mit hoher Wahrscheinlichkeit für das Vorliegen eines Fibrosestadiums II/III assoziiert. Wenn beide dieser Kriterien erfüllt waren, bestand zu 61 % ein Fibrosestadium II/II. Wenn hingegen keines der beiden Kriterien erfüllt war, lag die Wahrscheinlichkeit für eine Fibrose II/III lediglich bei 6 % (negativer prädiktiver Wert 94 %). Schlussfolgerung Die Kombination von LSM und NFS ermöglicht die Identifikation von Patienten mit erhöhtem Risiko für ein Fibrosestadium II/III. Daher könnte der Einsatz dieser beiden nicht-invasiven Tests speziell in Kombination als Screening-Tool für NAFLD-Patienten im Hinblick auf das Vorhandensein einer Fibrose II/III eingesetzt werden. Durch den Einsatz dieser Verfahren könnten außerdem nicht-notwendige Biopsien vermieden werden. Introduction Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent causes of chronic liver disease. Currently, therapeutic options for NAFLD patients are limited, but new pharmacologic agents are being investigated in the course of clinical trials. Because most of these studies are focusing on patients with fibrosis stages II and III (according to Kleiner), non-invasive identification of patients with intermediate fibrosis stages (II and III) is of increasing interest. Aims Evaluation of NAFLD Fibrosis Score (NFS) and liver stiffness measurement (LSM) for prediction of fibrosis stages II/III. Methods Patients with histologically confirmed NAFLD diagnosis were included in the study. All patients underwent a clinical and laboratory examination as well as a LSM prior to liver biopsy. Predictive value of NFS and LSM with respect to identification of fibrosis stages II/III was assessed. Results 134 NAFLD patients were included and analyzed. Median age was 53 (IQR 36 – 60) years, 55 patients (41 %) were female. 82 % of our patients were overweight/obese with typical aspects of metabolic syndrome. 84 patients (66 %) had liver fibrosis, 42 (50 %) advanced fibrosis. LSM and NFS correlated with fibrosis stage (r = 0.696 and r = 0.685, respectively; p < 0.01 for both). NFS values between –2.0 and + 0.5, and LSM values between 8 and 22kPa were associated with fibrosis stages II/III. If both criteria were met, probability of fibrosis stage II/III was 61 %. If none of the two criteria was met, chance for fibrosis stage II/III was only 6 % (negative predictive value 94 %). Conclusion Combination of LSM and NFS enables identification of patients with significant probability of fibrosis stage II/III. Accordingly, these tests, especially in combination, may be a suitable screening tool for fibrosis stages II/III in NAFLD. The use of these non-invasive methods might also help to avoid unnecessary biopsies.
- 1 December 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 56 (01) , 43-50
Kombination von NAFLD Fibrosis Score und transienter Elastografie zur Identifikation mittelgradiger Fibrosestadien (II/III) bei nicht-alkoholischer Fettlebererkrankung
Einleitung Die nicht-alkoholische Fettlebererkrankung (NAFLD) gehört mittlerweile weltweit zu den häufigsten Ursachen für eine chronische Leberschädigung. Aktuell sind die therapeutischen Optionen limitiert und neue pharmakologische Therapieoptionen werden primär im Rahmen von Studien untersucht. Da viele aktuelle Studien zumeist auf NAFLD-Patienten mit den Fibrosestadien II und III (nach Kleiner) abzielen, ist die nicht-invasive Identifikation dieser Patienten von zunehmender Bedeutung. Ziel Evaluation von Lebersteifigkeitsmessung (LSM) und NAFLD Fibrosis Score (NFS) im Hinblick auf die Vorhersage eines Fibrosestadiums II/III. Methoden Patienten mit bioptisch gesicherter NAFLD Diagnose wurden in die Studie eingeschlossen. Vor der Leberbiopsie wurden alle Patienten klinisch, laborchemisch und mittels LSM evaluiert. Anschließend wurde die Vorhersagekraft von NFS und LSM im Hinblick auf das Vorliegen einer Fibrose Stadium II/III untersucht. Ergebnisse 134 NALFD-Patienten wurden in die Studie eingeschlossen und untersucht. Das mittlere Alter betrug 53 (IQR 36 – 60) Jahre, 55 Patienten (41 %) waren weiblich. 82 % der Patienten waren übergewichtig/adipös mit typischen Befundkonstellationen des Metabolischen Syndroms. 84 Patienten (66 %) zeigten Zeichen einer Fibrose, bei 42 (50 %) bestand eine fortgeschrittene Fibrose. LSM und NFS korrelierten mit dem Fibrosestadium (r = 0,696 bzw. r = 0,685, p < 0,01). NFS-Werte zwischen –2,0 und + 0,5 und LSM-Werte zwischen 8 und 22kPa waren mit hoher Wahrscheinlichkeit für das Vorliegen eines Fibrosestadiums II/III assoziiert. Wenn beide dieser Kriterien erfüllt waren, bestand zu 61 % ein Fibrosestadium II/II. Wenn hingegen keines der beiden Kriterien erfüllt war, lag die Wahrscheinlichkeit für eine Fibrose II/III lediglich bei 6 % (negativer prädiktiver Wert 94 %). Schlussfolgerung Die Kombination von LSM und NFS ermöglicht die Identifikation von Patienten mit erhöhtem Risiko für ein Fibrosestadium II/III. Daher könnte der Einsatz dieser beiden nicht-invasiven Tests speziell in Kombination als Screening-Tool für NAFLD-Patienten im Hinblick auf das Vorhandensein einer Fibrose II/III eingesetzt werden. Durch den Einsatz dieser Verfahren könnten außerdem nicht-notwendige Biopsien vermieden werden. Introduction Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent causes of chronic liver disease. Currently, therapeutic options for NAFLD patients are limited, but new pharmacologic agents are being investigated in the course of clinical trials. Because most of these studies are focusing on patients with fibrosis stages II and III (according to Kleiner), non-invasive identification of patients with intermediate fibrosis stages (II and III) is of increasing interest. Aims Evaluation of NAFLD Fibrosis Score (NFS) and liver stiffness measurement (LSM) for prediction of fibrosis stages II/III. Methods Patients with histologically confirmed NAFLD diagnosis were included in the study. All patients underwent a clinical and laboratory examination as well as a LSM prior to liver biopsy. Predictive value of NFS and LSM with respect to identification of fibrosis stages II/III was assessed. Results 134 NAFLD patients were included and analyzed. Median age was 53 (IQR 36 – 60) years, 55 patients (41 %) were female. 82 % of our patients were overweight/obese with typical aspects of metabolic syndrome. 84 patients (66 %) had liver fibrosis, 42 (50 %) advanced fibrosis. LSM and NFS correlated with fibrosis stage (r = 0.696 and r = 0.685, respectively; p < 0.01 for both). NFS values between –2.0 and + 0.5, and LSM values between 8 and 22kPa were associated with fibrosis stages II/III. If both criteria were met, probability of fibrosis stage II/III was 61 %. If none of the two criteria was met, chance for fibrosis stage II/III was only 6 % (negative predictive value 94 %). Conclusion Combination of LSM and NFS enables identification of patients with significant probability of fibrosis stage II/III. Accordingly, these tests, especially in combination, may be a suitable screening tool for fibrosis stages II/III in NAFLD. The use of these non-invasive methods might also help to avoid unnecessary biopsies.